Journal of Immunology Research / 2010 / Article / Tab 3 / Clinical Study
Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis Table 3 Update (June 2009) of results on 24 patients treated with mDC vaccine.
Patient ID
vaccinationsDTH Best response after 4 or more vaccinations Vitiligo Clinical response Response duration OS (Months) ATL KLH (1) P.M 7
PR 3 14 (2) P.M 15
MR 6 22 (3) R.L. 10
SD 9 14 (4) G.D. 16
CR 8 34 (5) R.G. 4
PD — 8 (6) T.A. 13
MR 12 41 (7) B.A. 4
PD — 7 (8) C.P. 6
PD — 20 (9) O.M. 4
PD — 5 (10) LB. 4
PD — 3 (11) M.J. 8+8+8+4
CR
(12) O.G. 5
PD — 3 (13) M.R. 4
PD — 6 (14) DiI.G 10
CR
(15) B.F 21
PR
(16) I.I 6
PD — 7 (17) B.I 4
PR
(18) S.L 9
SD 7 22 (19) N.F. 6
PR 5 8 (20) B.R 12
SD 8 10 (21) S.M 11
PD — 12 (22) M.C 6
PD —
(23) R.G 5
PD —
(24) B.R 13
SD 11 16
PR: partial response; MR: mixed response; SD: stable disease; CR: complete response; PD: progressive disease; OS: overall survival; DTH: delayed-type hypersensitivity test;
obtained with palliative surgery
vaccine alternating; Grey area, 11 patients given postvaccine therapy.